Showing results (951-960 of 1,000) with videos related to

Sort By:
Pageof 100
Cancer Science|November 1, 2007
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208Yutaka Tokuda, Tomoo Tajima, Masaru Narabayashi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 13, 2019
GLCCI1 is a novel protector against glucocorticoid-induced apoptosis in T cellsZentaro Kiuchi, Yukino Nishibori, Satoru Kutsuna, et al.
Cancers|May 14, 2022
Tumor Microenvironment in Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: Interaction between Tumors and Immune Cells, and Potential Effects of Neuroendocrine Differentiation on the Tumor MicroenvironmentJunichi Tsunokake, Fumiyoshi Fujishima, Hirofumi Watanabe, et al.
Japanese Journal of Clinical Oncology|July 27, 1999
A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study GroupM Narabayashi, K Takeyama, T Fukutomi, et al.
Lancet (London, England)|June 7, 2016
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi, et al.
American Journal of Human Genetics|July 11, 2021
Genome-wide association study reveals an association between the HLA-DPB1∗02:01:02 allele and wheat-dependent exercise-induced anaphylaxisKoya Fukunaga, Yuko Chinuki, Yuto Hamada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancerM Ueno, T Okusaka, Y Omuro, et al.
Pancreas|April 24, 2018
Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in JapanAkiko Todaka, Nobumasa Mizuno, Masato Ozaka, et al.
Journal of Gastroenterology|April 16, 2026
Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01)Kazunaga Ishigaki, Yousuke Nakai, Kousuke Kashiwabara, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01)Yasuhiro Hagiwara, Yasuo Ohashi, Katsuhiko Uesaka, et al.
Pageof 100